ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has revealed new research indicating that analysing entire tumour cells in the bloodstream, rather than solely DNA fragments, may offer a more comprehensive understanding
Angle PLC (AIM:AGL OTCQX:ANPCY) Study of ovarian cancer CTCs using Parsortix
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has reported encouraging results from a study using its Parsortix system to predict progression-free survival among ovarian cancer
Angle PLC ( AIM:AGL OTCQX:ANPCY) Breakthrough clinical results
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a specialist in liquid biopsy, announced a significant advancement in cancer diagnostics, offering more personalized and actionable insights into the disease and its progression.